Drugs / TOP1630
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03088605 | Feb → Jun 2017 | dry eye syndrome | ORA, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03833388 | Feb → May 2019 | dry eye syndrome | Topivert Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOP1630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03088605 ↗ |
| Route | Other | “Bilateral ocular drug administration” NCT03088605 ↗ |